loading
Overview News Price History Discussions Forecast
Liminatus Pharma Inc stock is traded at $7.28, with a volume of 24,963. It is up +45.26% in the last 24 hours and up +0.00% over the past month. Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.
See More
Previous Close:
$5.30
Open:
$5.78
24h Volume:
24,963
Relative Volume:
3.56
Market Cap:
$54.43M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+68.84%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
Value
$5.30
$7.75
1-Week Range:
Value
$4.55
$7.75
52-Week Range:
Value
$4.40
$9.4003

Liminatus Pharma Inc Stock (LIMN) Company Profile

Name
Name
Liminatus Pharma Inc
Name
Sector
Healthcare (1169)
Name
Industry
Biotechnology (665)
Name
Phone
-
Name
Address
-
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
LIMN's Discussions on Twitter

Compare LIMN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
LIMN
Liminatus Pharma Inc
 7.699 141.59M 0 0 0 0.00
Biotechnology icon
ONC
Beone Medicines Ltd Adr
 258.49 26.01B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
 447.98 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
 1.3499 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
 85.30 6.29B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
 487.87 65.13B 14.09B 4.50B 2.96B 39.28

Liminatus Pharma Inc Stock (LIMN) Latest News

pulisher
May 15, 2025

Liminatus Pharma Delays Quarterly Report Filing - TipRanks

May 15, 2025
pulisher
May 14, 2025

Liminatus Pharma’s Merger with Iris Acquisition Corp. - Global Legal Chronicle

May 14, 2025
pulisher
May 01, 2025

Iris Acquisition, Liminatus Pharma Sign SPAC Merger Deal - marketscreener.com

May 01, 2025
pulisher
Mar 10, 2025

Iris Acquisition Corp confirms delisting and shareholder vote outcomes - Investing.com

Mar 10, 2025
pulisher
Jan 28, 2025

Iris Acquisition Corp announces preliminary proxy statement - Investing.com

Jan 28, 2025
pulisher
Nov 11, 2024

Iris Acquisition Corp announces business combination - Investing.com

Nov 11, 2024
pulisher
Aug 07, 2024

Iris Acquisition Corp announces business combination with Liminatus Pharma - Investing.com

Aug 07, 2024
pulisher
Dec 05, 2022

New company Liminatus Pharma Inc to develop three cancer treatments - Labiotech.eu

Dec 05, 2022
pulisher
Dec 02, 2022

A fledgling biotech goes SPAC route to bankroll cancer vaccine, CAR-T and CD47 - Endpoints News

Dec 02, 2022
pulisher
Dec 01, 2022

Liminatus Pharma and Iris Acquisition to Combine in $334M Deal - The SPAC Conference

Dec 01, 2022
pulisher
Nov 30, 2022

Liminatus Pharma and Iris Acquisition Corp to Combine - citybiz

Nov 30, 2022
pulisher
Mar 20, 2017

Holland & Knight Partner Seth Belzley Ranked Among Denver’s Outstanding "40 Under 40" Business Professionals - Holland & Knight

Mar 20, 2017

Liminatus Pharma Inc Stock (LIMN) Financials Data

There is no financial data for Liminatus Pharma Inc (LIMN). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Similar to LIMN

biotechnology BDRX
$1.16
price up icon 0.87%
biotechnology ZLAB
$31.13
price down icon 0.19%
biotechnology ARGX
$576.61
price down icon 1.37%
biotechnology ALNY
$303.77
price down icon 0.76%
biotechnology ATHE
$4.5807
price down icon 0.41%
biotechnology REGN
$487.86
price up icon 0.56%
Open in Yahoo | Open in Google | Open in Finviz | Open in MarketWatch | Open in EDGAR | Open in Reuters
Cap:     |  Volume (24h):